Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Trial Profile

Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Fulranumab (Primary) ; Celecoxib
  • Indications Pain
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 25 Nov 2016 This trial was discontinued in Germany, according to European Clinical Trials Database.
    • 14 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 05 Oct 2016 This trial has been discontinued in Spain (end date: 19 Sep 2016) and completed in Hungary (end date: 19 Sep 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top